These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2153391)

  • 1. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
    Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
    Caporaso N; Hayes RB; Dosemeci M; Hoover R; Ayesh R; Hetzel M; Idle J
    Cancer Res; 1989 Jul; 49(13):3675-9. PubMed ID: 2731181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer and the debrisoquine metabolic phenotype.
    Caporaso NE; Tucker MA; Hoover RN; Hayes RB; Pickle LW; Issaq HJ; Muschik GM; Green-Gallo L; Buivys D; Aisner S
    J Natl Cancer Inst; 1990 Aug; 82(15):1264-72. PubMed ID: 2374176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic oxidation of debrisoquine in lung cancer patients.
    Benítez J; Ladero JM; Jara C; Carrillo JA; Cobaleda J; Llerena A; Vargas E; Muñoz JJ
    Eur J Cancer; 1991; 27(2):158-61. PubMed ID: 1827280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
    Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
    Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Boobis AR; Davies DS
    Br J Clin Pharmacol; 1990 Oct; 30(4):653-6. PubMed ID: 2291880
    [No Abstract]   [Full Text] [Related]  

  • 12. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
    Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
    Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
    Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debrisoquine oxidation in an Australian population.
    Peart GF; Boutagy J; Shenfield GM
    Br J Clin Pharmacol; 1986 May; 21(5):465-71. PubMed ID: 3718805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
    Horsmans Y; Desager JP; Harvengt C
    Biomed Pharmacother; 1991; 45(8):359-62. PubMed ID: 1773024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.